

## Curriculum Vitae

### Rüdiger HEHLMANN, o. Prof. Dr. med. Dr. h. c.

**Personal Data** Business address:  
Medizinische Fakultät Mannheim, Universität Heidelberg,  
and ELN Foundation, Im Langgewann 45, 69469 Weinheim  
hehlmann.eln@gmail.com  
Married to: Dr. Annemarie Hehlmann,  
Date and place of birth: 10.5.1941, Halle/Saale, Germany

#### Education

1961 - 1966 Study of Medicine at Marburg, Freiburg, Edinburgh, Munich  
Graduation: December 1966  
Stevenson Exchange Scholar (Edinburgh) 1964-1965  
Studienstiftung des Deutschen Volkes 1963-1969

1967 - 1969 Internship in Gynecology, Surgery and Medicine, Munich University  
MD-PhD Scholar, Max Planck Institut für Biochemie, Munich (P.H. Hofschneider). Graduation: July 1969



#### Academic Career

1969 - 1970 Assistant, Max-Planck-Institut für Biochemie, Munich

1970 Research Fellow, University of Rochester, New York (Stan Hattman)

1970 - 1973 Research Associate (Sol Spiegelman) and Lecturer in Human Genetics and Development at Columbia University, New York

1973 - 1974 Intern in Medicine, Columbia-Presbyterian Medical Center  
Licence to practice Medicine and Surgery in the State of New York, 16.9.1974

1974 DFG (German Research Council)-stipend, Clinical Fellow at Memorial Sloan Kettering Cancer Center (Bayard Clarkson)

1974 - 1981 Assistant, Medizinische Poliklinik, Munich University (Nepomuk Zöllner)

1977 Boards as Internist

1979 Habilitation (Dr. med. habil.)

1981 - 1988 Professor of Medicine, Munich University

1984 Boards as Hematologist and Medical Oncologist

1975 - 1988 Laboratory research at GSF, Neuherberg (in cooperation with Volker Erfle)

1988 - present Professor of Medicine, Heidelberg University

1988 - 2007 Director, III. Medizinische Universitätsklinik Mannheim

1999 - 2001 Dean, Mannheim Medical Faculty

2007 - 2017 Research Professorship Mannheim Medical Faculty

1995 - 2009 President and Secretary General, International Association for Comparative Research and Leukemia and Related Diseases (IACRLRD)

2000 - 2001 President, German Society for Hematology and Oncology

2009 Congress president, 14. Congress of the European Hematology Association, Berlin

## **Research**

1970-1990 Search for a human leukemia virus.

Results: detection of retrovirus-related RNA and reverse transcriptase in human cells; isolation, in 1983, of a complete human endogenous retrovirus related to a primate leukemia virus; first HIV-seroepidemiology in Germany (1984)

Since 1982 Shift towards clinical trials on chronic myeloid leukemia (CML).  
Founder and chair of the German CML study group.

1982-2017 Randomized treatment optimization studies on CML: hydroxyurea, interferon  $\alpha$ , SCT, imatinib. Profound improvement of prognosis and survival in CML.

Since 1992 European cooperation on clinical CML-research (European Investigators on CML).

1997-2006 Studies on carcinogenesis:  
Demonstration of relevance of chromosomal aberrations (aneuploidy) for genetic instability and cancer development in a hamster model (in cooperation with Peter Duesberg). Chromosomal theory of carcinogenesis.

Since 1997 German competence network on acute and chronic leukemias in cooperation with all major German leukemia trial groups. Improvement and acceleration of German leukemia research resulting in greater international visibility.

Since 2002 European LeukemiaNet (ELN):  
ELN has established common standards and guidelines for all major leukemias and interdisciplinary specialties across Europe.  
ELN management recommendations (more than 100) have become international standards for diagnosis and therapy. Second editions for AML, MPN and APL in 2017, 2018 and 2019 and fourth edition for CML in 2020.

2007-2015 Public private partnership of ELN with Novartis:  
European Treatment and Outcome Study (EUTOS) for CML to determine the epidemiology of CML, define standards for molecular monitoring and spread excellence in Europe.

Since 2015 ELN participation in the Horizon 2020 project MDS-RIGHT

Since 2017 ELN participation in the IMI project HARMONY

2020 ELN participation in the IMI project HARMONY PLUS

2014-2020 Demonstration that additional chromosomal aberrations at low blast counts herald death by CML.

## **Research support:**

Mostly public and foundations (EU, BMBF, Krebshilfe, Carreras, DFG), one third industry.

## Honors

1984	Curt Bohneward-Prize for scientific cooperation in cancer research
1990	GSF-Prize for interdisciplinary cooperation
1999	Paul Martini-Prize for improvement of prognosis in CML
2000	Ehrenschild, Kulturverein Waldhof
2004	R.T. Silver-Lecture, Cornell University, New York
2005	Honorary Member of the Polish Society for Hematology and Transfusion Medicine
2006	Wiedermann-Lecture, Olmütz, Czechia
2007	Hofschneider-Memorial Lecture, XXIII. IACRLRD-Symposium, Freiburg
2008	Honorary Member of the German Society for Hematology and Oncology
2009	Johann Georg Zimmermann-Medal for the treatment of leukemia
2011	Jubilee lecture 50 years IACRLRD, Tokyo, Japan
2011	Honorary doctor of the University Uppsala, Sweden
2012	Wilhelm Warner-Prize for the fight against cancer
2013	Sol Spiegelman-Memorial Lecture, XXVI. IACRLRD-Symposium, Turin, Italy
2014	John Goldman-Prize with lecture, Philadelphia, USA
2016	John Goldman Lecture, Santa Magherita, Italy
2016	Raisa Gorbachova Lecture, St. Petersburg, Russia
2017	Kenneth McCredie-Memorial Lecture, XXVIII. IACRLRD-Symposium, Houston, USA
2019	Award of Excellence in Translational Research, New York, USA
2019	Frank Rauscher-Memorial Lecture, XXIX. IACRLRD-Symposium, Seoul, Korea

## International Congresses and Meetings (82)

1992 - 2017	25 Annual International Workshops on CML in Weinheim, Mannheim and Heidelberg
1997, 2005	XIX., and XXII. Symposium of the IACRLRD in Mannheim and Heidelberg
2001	Annual Congress of the German and Austrian Societies of Hematology and Oncology in Mannheim
2003	11 <sup>th</sup> Annual Meeting of the European Investigators on CML in Berlin
1999 - 2003	4 Annual Symposia of the Competence Network “Akute und chronische Leukämien” in Heidelberg (KNL-Symposia)
2004 - 2019	16 Annual Symposia of the German and European Leukemia Networks in Heidelberg, Mannheim and Venice (ELN-Symposia)
2002 - 2019	18 Annual Meetings of the European LeukemiaNet (ELN) at ASH conferences in Philadelphia, Atlanta (4x), San Diego (5x), Orlando (4x), San Francisco (2x) and New Orleans (2x) (ELN Breakfast Meetings)

- 2006 - 2014 9 ELN-Frontiers Meetings in Venice, Budapest, Cannes, Barcelona, Vienna, Prague, Istanbul, Berlin (2x)
- 2009 - 2014 6 ELN-Educational Meetings for young European hematologists in Naples, Italy (with F. Pane)

### **CML Study Group Meetings**

- 1982 - 2017 Ca. 70 meetings in Günzburg (Reisensburg), Weinheim (Wachenburg), Heidelberg and Mannheim

### **Career-related Activities**

- 1981 - 1988 Vice chairman, Society for Morphology and Physiology, Munich
- 1986 - 1990 Vice chairman, Süddeutsche Hämoblastosegruppe (SHG)
- 1987 Advisor, AIDS-Hearing at the Bavarian Parliament (Bayerischer Landtag)
- 1987 - 1988 Advisor, Enquete Commission on AIDS of the German Parliament (Bundestag)
- 1989 - 1991 Delegate (Fachvertreter) for AIDS of the German Ministry for Research and Technology at the European Commission in Brussels
- 1989 - 2009, 2013 - present World Committee of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD)
- 1997 - 2009 Secretary General of the IACRLRD
- 1990 - 2008 Steering Committee, Cancer Center Heidelberg/Mannheim
- 2005 - 2007 Steering Committee, Interdisciplinary Tumor Center Mannheim (ITM)
- 1996 Advisory Committee Cost evaluation of clinical university medicine of the German Government
- 1993 - 1998 Review Committee Infectious Diseases of the German Ministry for Research and Technology
- 1995 - 1999 Review Committee Public Health of the German Ministry for Research and Technology
- 1995 - present Scientific Advisory Board, José Carreras Leukämie Stiftung
- 1996 - 2000 CML-Guidelines Committee of the American Society of Hematology
- 1996 - 2004 Advisory Board of the German Society for Hematology and Oncology
- 1997 - 2000 Delegate of the German Society for Hematology and Oncology to the Working Party of Scientific Medical Societies (AWMF)
- 1996 - 2007 Section Editor for CML of Leukemia
- 1996 - 2017 Editorial Boards of Annals of Hematology, European Journal of Medical Research, others
- 1997 - present Founder and Chair Kompetenznetz Akute und chronische Leukämien
- 2001 - 2017 Steering Committee of the German AML Intergroup
- 2002 - present Founder and Chair, Stiftung Leukämie (supporting Kompetenznetz Leukämien)
- 2002 - present Founder and Chair, European LeukemiaNet (ELN)
- 2009 - present Founder and Chair, ELN-Foundation (supporting ELN)

**Publications :** 450 medline-listed, 125 others (book chapters, translations, articles, reviews)

Editor : AIDS-Forschung (AIFO). Schulz 1986-1996  
Chronic Myeloid Leukemia. Springer 2016

Guest Editor : Best Practice & Research in Clinical Haematology 2009  
Annals of Hematology 2015

Article on R. Hehlmann: Cancer. 2017, Sept 1; 3209-3210

### **Selected Publications (2011 - 2020) :**

**Hehlmann R**, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb H-J, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußebe S, Baccarani M for the SAKK and the German CML Study Group. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. *Leukemia*. 2020

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, ... **Hehlmann R**. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*. 2020; 10.1038/s41375-020-0776-2. Advance online publication. <https://doi.org/10.1038/s41375-020-0776-2>

**Hehlmann R**, Cortes JE, Zyczynski T, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. *Am J Hematol*. 2019;94(1):46–54. doi:10.1002/ajh.25306

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, **Hehlmann R**, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.

Saussele S, **Hehlmann R**, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. *Leukemia*. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.

**Hehlmann R**. Advancing a field by building consortia: The example of the European LeukemiaNet. *Cancer*. 2018 Mar 15;124(6):1100-1104. doi: 10.1002/cncr.31199. Epub 2018 Feb 16.

**Hehlmann R**, Lauseker M, Saußebe S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML

study IV and impact of non-CML determinants. *Leukemia*. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

Khoury HJ, Williams LA, Atallah E, **Hehlmann R**. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. *Am Soc Clin Oncol Educ Book*. 2017; 37:468-479. doi: 10.14694/EDBK\_175712.

Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, **Hehlmann R**. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. *J Cancer Res Clin Oncol*. 2017 Jul;143(7):1311-1318. doi: 10.1007/s00432-017-2385-7. Epub 2017 Mar 8.

Lauseker M, Hasford J, Saussele S, Kremers S, Kraemer D, Lindemann W, **Hehlmann R**, Pfirrmann M; German CML Study Group. Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. *Cancer*. 2017 Jul 1;123(13):2467-2471. doi: 10.1002/ncr.30636. Epub 2017 Feb 13.

**Hehlmann R**, Sauße S, Voskanyan A, Silver RT. Management of CML-blast crisis. *Best Pract Res Clin Haematol*. 2016 Sep; 29(3):295-307. doi: 10.1016/j.beha.2016.10.005. Review.

**Hehlmann R**. Innovation in Hematology. Perspectives : CML 2016. *Haematologica*. 2016 Jun;101(6):657-9.

Stegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, **Hehlmann R**, Clark RE. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*. 2016 Jun 3 ; 30, 1648-1671. doi: 10.1038/leu.2016.104. Review.

Kossak-Roth U, Sauße S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G, Ganser A, Giagounidis A, Gökbuget N, Griesshammer M, Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, **Hehlmann R**. [Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2016 Apr; 59(4):444-53. doi: 10.1007/s00103-016-2315-x. German.

Büchner T, Krug UO, Gale RP, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, **Hehlmann R**, Wörmann BJ, Berdel WE, Hiddemann W. Age, not therapy-intensity, determines outcomes of adults with acute myeloid leukaemia. *Leukemia*. 2016 Aug; 30(8):1781-4..

Padula WV, Larson RA, Dusetzina SB, Apperley JF, **Hehlmann R**, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. *J Natl Cancer Inst*. 2016 Mar 4;108(7).

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, **Hehlmann R**, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. *Leukemia*. 2016 Jun; 30(6):1230-6.

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baumann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Sauße S, Hochhaus A,

**Hehlmann R.** Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment. *Leukemia* 2016; 30:562-569

Pfirschmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, **Hehlmann R**, Simonsson B. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia *Leukemia*. 2016 Jan;30(1):48-56.

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirschmann M, Hasford J, Krause S, Hochhaus A, Sauße S, **Hehlmann R**; SAKK and the German CML Study Group. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. *Ann Hematol*. 2015 Dec;94(12):2015-24

Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, **Hehlmann R**. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. *Leukemia*. 2015 Jun;29(6):1336-43

**Hehlmann R.** CML--Where do we stand in 2015? *Ann Hematol*. 2015 Apr;94 Suppl 2:S103-5

Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirschmann M, Hochhaus A, Hasford J, **Hehlmann R**. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. *Leukemia*. 2015 May;29(5):1123-32

Talpaz M, Mercer J, **Hehlmann R**. The interferon-alpha revival in CML. *Ann Hematol*. 2015 Apr;94 Suppl 2:S195-207

Sauße S, Krauß MP, **Hehlmann R**, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Oppliger Leibundgut E, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirschmann M, Müller MC. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML-Study IV. *Blood*. 2015 Apr 27. pii: blood-2015-01-617993

Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, **Hehlmann R**, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Clinical endpoints for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). *Leukemia*. 2014 Aug 25

Hanfstein B, Shlyakhto V, Lauseker M, **Hehlmann R**, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirschmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; for the SAKK and the German CML Study Group. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib *Leukemia*. 2014 Oct;28(10):1988-92

Pfirschmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, **Hehlmann R**; for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. *J Cancer Res Clin Oncol*. 2014 Aug;140(8):1367-81

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pffirmann M, Hochhaus A, Hasford J, **Hehlmann R**, Saußebe S; for the German Chronic Myeloid Leukemia Study Group, and the SAKK. Older patients with chronic myeloid leukemia ( $\geq 65$  years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. *Ann Hematol*. 2014 Jul;93(7):1167-76

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pffirmann M, Fabarius A, Schlegelberger B, Saußebe S, Dietz CT, Erben P, **Hehlmann R**, Hasford J, Hochhaus A, Müller MC. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. *J Cancer Res Clin Oncol*. 2014;140:1965-9

Lauseker M, Hasford J, Pffirmann M, **Hehlmann R**; German CML Study Group. The impact of health care settings on survival time of patients with chronic myeloid leukemia. *Blood*. 2014 Apr 17;123(16):2494-6

**Hehlmann R**, Müller M C, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pffirmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge Ch, Kanz L, Neubauer A, Kneba M, Stegelmann Fr, Pfreunds Schuh M, Waller C F, Spiekermann K, Baerlocher G M, Ehninger G, Heim D, Heimpel H, Nerl Ch, Krause S W, Hossfeld D K, Kolb H-J, Hasford J, Saußebe S, and Hochhaus A. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. *J Clin Oncol*. 2014 Feb 10;32(5):415-23

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pffirmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreunds Schuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, **Hehlmann R**; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. *Ann Hematol*. 2014 Jan;93(1):71-80

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußebe S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, **Hehlmann R**. European LeukemiaNet recommendations for the management of chronic myeloid *Blood*. 2013 Aug 8;122(6):872-84

Talpa M, **Hehlmann R**, Quintás-Cardama A, Mercer J, Cortes J. Re-emergence of interferon- $\alpha$  in the treatment of chronic myeloid leukemia. *Leukemia*. 2013 Apr;27(4):803-12

Horn M, Glauche I, Müller MC, **Hehlmann R**, Hochhaus A, Loeffler M, Roeder I. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. *Blood*. 2013 Jan 10;121(2):378-84

Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Späth D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, **Hehlmann R**, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pffirmann M. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. *J Clin Oncol*. 2012 Oct 10;30(29):3604-10

**Hehlmann R**. How I treat CML blast crisis. *Blood*. 2012 Jul 26;120(4):737-47

Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritsky A, **Hehlmann R**. Definitions, methodological, and statistical issues for phase III clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. *Blood*. 2012 Jun 21;119(25):5963-71



Hanfstein B, Müller MC, **Hehlmann R**, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). *Leukemia*. 2012 Sep;26(9):2096-102

Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, **Hehlmann R**; SAKK and the German CML Study Group. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. *Blood*. 2011, 118(26):6760-8

Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, **Hehlmann R**, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. *Leukemia*. 2011;25(9):1433-8

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, **Hehlmann R**. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. *Blood*. 2011, 118(3):686-92

**Hehlmann R**, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, et.al. Tolerability-adapted imatinib 800 mg vs 400 mg vs. 400 mg + IFN in newly diagnosed chronic myeloid leukemia. *J Clin Oncol* 2011, 29(12):1634-42

**Hehlmann R**, Jung-Munkwitz S, Saussele S. Treatment of chronic myeloid leukemia when imatinib fails. *Expert Opin Pharmacother*. 2011; 12(2):269-83

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, **Hehlmann R**, et.al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. *J Clin Oncol*. 2011, 29(6):761-70

**Hehlmann R**, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, et.al. The European LeukemiaNet: achievements and perspectives. *Haematologica*. 2011; 96(1):156-62